These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2969799)

  • 1. Comparison between the effects of urapidil and methyldopa on left ventricular hypertrophy and haemodynamics in humans.
    Feldstein CA; Olivieri AO; Sabarís RP
    Drugs; 1988; 35 Suppl 6():90-7. PubMed ID: 2969799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in left ventricular function and structure in hypertensive patients treated with methyldopa and urapidil].
    Rakić D; Rumboldt Z; Polić S; Obad M; Bagatin J
    Lijec Vjesn; 1990; 112(3-4):89-94. PubMed ID: 2204776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of urapidil and atenolol in hypertension.
    Török E; Wagner M; Podmaniczky M
    Drugs; 1988; 35 Suppl 6():164-72. PubMed ID: 3042356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of urapidil in the management of essential hypertension. A comparison with captopril.
    Rosenthal J; Haerlin R; Schäfer N; Christ B; Wurst W
    Drugs; 1988; 35 Suppl 6():147-55. PubMed ID: 3042354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind comparison of urapidil and prazosin in the treatment of patients with essential hypertension.
    Kaneko Y
    Drugs; 1988; 35 Suppl 6():156-63. PubMed ID: 3042355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic assessment of urapidil or angiotensin-converting enzyme inhibition in systemic hypertension.
    Rosenthal J; Haerlin R
    Am J Cardiol; 1989 Aug; 64(7):25D-29D. PubMed ID: 2667311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antihypertensive effect and tolerance to urapidil. Comparison with nifedipine in a multicenter double-blind study].
    Stumpe KO; Feldhaus P; Haerlin R
    Fortschr Med; 1989 Jan; 107(1):54-7. PubMed ID: 2646188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic haemodynamic and humoral changes during urapidil treatment in hypertensive patients.
    Leonetti G; Terzoli L; Zanchetti A
    J Hypertens Suppl; 1988 Dec; 6(2):S25-9. PubMed ID: 2906697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of clinical trials with urapidil.
    Schook CE; Radtke H; Wurst W; Thieme G
    Am J Cardiol; 1989 Aug; 64(7):30D-37D. PubMed ID: 2667312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of prazosin as the sole agent for the treatment of hypertension: a double-blind cross-over study with methyldopa.
    Bloom DS; Rosendorff C; Kramer R
    Curr Ther Res Clin Exp; 1975 Jul; 18(1 pt 2):144-50. PubMed ID: 809230
    [No Abstract]   [Full Text] [Related]  

  • 11. Antihypertensive effects of urapidil and clonidine: a double-blind cross-over study.
    Kanniainen E; Heikkilä O; Jääskeläinen T; Lilja M; Jounela AJ
    Eur J Clin Pharmacol; 1985; 28(1):35-9. PubMed ID: 3886400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time course of regression of left ventricular hypertrophy in treated hypertensive patients.
    Wollam GL; Hall WD; Porter VD; Douglas MB; Unger DJ; Blumenstein BA; Cotsonis GA; Knudtson ML; Felner JM; Schlant RC
    Am J Med; 1983 Sep; 75(3A):100-10. PubMed ID: 6226186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel therapeutic approach for reversal of left ventricular hypertrophy and blood pressure control in hypertensive patients treated with alpha-methyldopa or propranolol.
    Fernandez PG; Snedden W; Kim BK; Lee CC
    Can J Physiol Pharmacol; 1985 Apr; 63(4):304-8. PubMed ID: 3159468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of urapidil in the management of essential hypertension: a comparison with captopril.
    Rosenthal J; Haerlin R
    J Hypertens Suppl; 1988 Dec; 6(2):S69-71. PubMed ID: 3068344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Lack of association with blood pressure control.
    Fouad FM; Nakashima Y; Tarazi RC; Salcedo EE
    Am J Cardiol; 1982 Mar; 49(4):795-801. PubMed ID: 6461238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind studies of the clinical effectiveness of prazosin.
    Schnaper HW; Oberman A
    Postgrad Med; 1975 Nov; Spec No():81-7. PubMed ID: 1105489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Guanfacine versus alpha-methyldopa in benign essential hypertension. An ambulatory group study].
    Rhomberg F; Widler J
    Schweiz Med Wochenschr; 1981 Dec; 111(50):1967-8. PubMed ID: 7036334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-term antihypertensive therapy on cardiac anatomy in patients with essential hypertension.
    Drayer JI; Weber MA; Gardin JM; Lipson JL
    Am J Med; 1983 Sep; 75(3A):116-20. PubMed ID: 6226188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of antihypertensive activity and tolerability of guanfacine and methyldopa.
    Malini PL; Strocchi E; Ambrosioni E; Magnani B
    Int J Clin Pharmacol Res; 1983; 3(1):35-9. PubMed ID: 6384071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
    Farooki MS; Farsky K; Bouchard S; Lalonde Y; Brookman S
    Clin Ther; 1985; 7(2):199-204. PubMed ID: 3886142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.